ClinicalTrials.gg
CompletedNCT07864610Updated Oct 8, 2026

Rigid Taping for Increased Elbow Valgus

An interventional study of Rigid Taping and Placebo Taping in Elbow, sponsored by Gazi University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Gazi University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Mar 2024, registered Oct 2026).
Updated Oct 8, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 25 Years
Sex
All
01

Study summary

This study aims to investigate the acute effects of rigid taping based on the Mulligan Concept on elbow valgus angle, hand grip strength, and pinch strength in healthy young adults with an elbow valgus angle of 15 degrees or greater.

A total of 25 healthy young adults aged 18 to 25 years were randomly assigned to either an experimental group receiving rigid taping or a control group receiving placebo taping. Elbow valgus angle, hand grip strength, and three types of pinch strength (lateral, tip, and three-point pinch) were assessed at baseline (before taping) and 20 minutes after the taping application.

The main objective is to determine whether rigid taping based on the Mulligan Concept provides greater immediate improvements in elbow valgus angle, hand grip strength, and pinch strength compared with placebo taping.

02

Conditions studied

  • Elbow

Keywords

  • Elbow valgus angle
  • Rigid taping
  • Mulligan concept
  • Hand grip strength
  • Pinch strength
  • Upper extremity
03

In context

Lead sponsor

Gazi University is the lead sponsor of 548 studies on the registry; 104 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 25 years and healthy young adult
  • Elbow valgus angle of 15 degrees or greater.
  • Body mass index between 18.5 and 24.9 kg/m².
  • Voluntary agreement to participate in the study and provision of written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Known allergy to rigid tape material.
  • Neurological, orthopedic, or rheumatological disease that could affect upper extremity function.
  • History of trauma or surgery that could affect upper extremity biomechanics or muscle function.
  • Regular use of medication that could affect upper extremity muscle strength or function.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Rigid Taping

    Participants received rigid taping based on the Mulligan Concept to reduce the elbow valgus angle.

    Behavioral: Rigid Taping

  • Placebo comparator
    placebo taping

    Participants received placebo taping without a corrective force or biomechanical correction.

    Behavioral: Placebo Taping

Interventions

  • BehavioralRigid Taping

    Rigid taping was performed based on the biomechanical correction principles of the Mulligan Concept, a manual therapy approach aimed at supporting joint alignment and improving biomechanical control during functional movement. As no standardized Mulligan taping protocol specifically targeting an increased elbow valgus angle has been identified in the literature, the taping technique used in this study was standardized by the researchers based on the biomechanical correction principles of the Mulligan Concept. Participants were seated with the elbow in full extension and the forearm in supination. Before tape application, a lateral corrective force was applied to the distal humerus by the researcher and a medial corrective force was applied to the forearm by an independent researcher to reduce the elbow valgus angle. The corrected position was maintained by both researchers while the tape was applied by the researcher.

  • BehavioralPlacebo Taping

    Placebo taping was applied using rigid tape without applying any corrective force. The tape was placed over the same anatomical region in all participants in a manner that did not alter elbow joint alignment or produce biomechanical correction. All placebo taping applications were performed by the same physiotherapist.

06

What researchers measure

Primary outcomes

  1. Elbow valgus angle

    Elbow valgus angle was assessed before taping and 20 minutes after the taping application. Participants were positioned standing with the shoulder in a neutral position, the elbow in full extension, and the forearm in supination. A digital camera mounted on a fixed tripod was used, and all images were obtained from the same distance, height, and angle. Anatomical reference points defining the longitudinal axes of the humerus and ulna were marked on the skin. Digital images were analyzed using ImageJ software (National Institutes of Health, Bethesda, MD, USA).

    Time frame: Baseline and 20 minutes after taping

Secondary outcomes

  1. Hand grip strength

    Hand grip strength was assessed before taping and 20 minutes after the taping application using a Jamar® Hydraulic Hand Dynamometer (Baseline®, Fabrication Enterprises Inc., White Plains, NY, USA). Measurements were performed in the standardized assessment position recommended by the American Society of Hand Therapists (ASHT). Three measurements were obtained, and the mean of the three measurements was used for analysis.

    Time frame: Baseline and 20 minutes after taping

  2. Lateral pinch strength

    Lateral pinch strength was assessed before taping and 20 minutes after the taping application using a Baseline® Hydraulic Pinch Gauge (Fabrication Enterprises Inc., White Plains, NY, USA). Measurements were performed according to the standardized assessment position recommended by the American Society of Hand Therapists (ASHT). Three measurements were obtained, and the mean of the three measurements was used for analysis. Results were recorded in kilogram-force (kgf).

    Time frame: Baseline and 20 minutes after taping

  3. Tip pinch strength

    Tip pinch strength was assessed before taping and 20 minutes after the taping application using a Baseline® Hydraulic Pinch Gauge (Fabrication Enterprises Inc., White Plains, NY, USA). Measurements were performed according to the standardized assessment position recommended by the American Society of Hand Therapists (ASHT). Three measurements were obtained, and the mean of the three measurements was used for analysis. Results were recorded in kilogram-force (kgf).

    Time frame: Baseline and 20 minutes after taping

  4. Three-point pinch strength

    Three-point pinch strength was assessed before taping and 20 minutes after the taping application using a Baseline® Hydraulic Pinch Gauge (Fabrication Enterprises Inc., White Plains, NY, USA). Measurements were performed according to the standardized assessment position recommended by the American Society of Hand Therapists (ASHT). Three measurements were obtained, and the mean of the three measurements was used for analysis. Results were recorded in kilogram-force (kgf).

    Time frame: Baseline and 20 minutes after taping

07

Study locations

1 site
  • Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation
    Ankara, Ankara 06500, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Jul 2026, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2026
First posted
Oct 8, 2026
StartActual
Mar 23, 2024
Primary completionActual
Jul 23, 2026
CompletionActual
Jul 23, 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07864610
Lead sponsor
Gazi University
Responsible party
Merve BAYRAK (Master's Student, Gazi University) — Principal investigator
First posted
Oct 8, 2026
Start date
Mar 23, 2024
Primary completion
Jul 23, 2026
Completion
Jul 23, 2026
Last update
Oct 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion